Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive...
Ophthalmology
AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products
AbbVie Inc. (NYSE: ABBV), the US pharmaceutical giant, has announced a strategic partnership with the...
Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration
Gan & Lee Pharmaceuticals (SHA: 603087) has announced that China’s National Medical Products Administration (NMPA)...
Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision
Shionogi & Co., Ltd. (TYO: 4507) has announced the completion of its first corporate venture...
Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response
Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating...
Merck Launches Pivotal Phase 2b/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment
Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b/3...
Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections
Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8...
Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases
Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced the initiation of a Phase II clinical...
Formosa Pharmaceuticals Licenses APP13007 to Arrotex – Nanoparticle Ophthalmic Steroid Gains Australia/New Zealand Rights
Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Arrotex Pharmaceuticals Pty Ltd., granting the...
Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China
Grand Pharmaceutical Group (HKG: 0512) announced that its licensed‑in global innovative ophthalmic drug GPN01768 [TP‑03,...
VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline
VivaVision Biotech (Zhejiang) Co., Ltd., an ophthalmology-focused biotech company founded in 2016, has submitted its...
uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases
uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership...
ZEISS ARTEVO Gets NMPA Approval for China Ophthalmology Market
ZEISS Medical Technology announced that the National Medical Products Administration (NMPA) has approved the ARTEVO...
Arctic Vision-Mdco Technology Merger Builds Ophthalmology Platform
Arctic Vision, a China‑based ophthalmology specialist, and Mdco Technology Co., Ltd. have agreed to integrate...
Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
Zhaoke Ophthalmology (HKG: 6622) announced that its UK partner Tenpoint Therapeutics has received FDA clearance...
Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam
Zhaoke Ophthalmology (HKG: 6622) announced expanded distribution agreements for BRIMOCHOL PF to include Singapore and...
Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
Ocumension Therapeutics (HKG: 1477) announced completion of enrollment for a real‑world study of OT-703 (fluocinonide...
Santen’s UPNEEQ Wins Japan Approval for Acquired Ptosis
Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved...
GenEditBio’s GEB-101 Wins FDA IND Approval as World’s First Corneal Gene Therapy
GenEditBio announced that GEB-101, its self‑developed in vivo genome editing investigational drug, has received Investigational...
Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its...